U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

(MARK ONE)

         [X]    QUARTERLY  REPORT  UNDER  SECTION 13 OR 15(d) OF THE  SECURITIES
                EXCHANGE ACT OF 1934

                       For the quarter ended June 30, 2000

         [ ]    TRANSITION  REPORT UNDER  SECTION 13 OR A5(d) OF THE  SECURITIES
                EXCHANGE ACT OF 1934 (no fee required)

                         Commission file number 0-23544

                         HUMAN PHEROMONE SCIENCES, INC.
                 -----------------------------------------------
                 (Name of small business issuer in its charter)

           California                                             94-3107202
-------------------------------                               ----------------
(State or other jurisdiction of                               (I.R.S. employee
 incorporation or organization)                              Identification No.)


47650 Fremont Blvd.  Suite 200, Fremont, California                  94538
---------------------------------------------------                ----------
    (Address of principal executive offices)                       (Zip code)

                    Issuer's telephone number: (510) 226-6874

         Check whether the Issuer (1) filed all reports  required to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing  requirements for the past 90 days.
Yes [ X ] No  [ ]

                   (APPLICABLE ONLY TO CORPORATE REGISTRANTS)

         State the number of shares  outstanding of each of the issuer's classes
of common equity, as of the latest practicable date.  3,429,839 shares of Common
Stock as of August 7, 2000.



<PAGE>


                         HUMAN PHEROMONE SCIENCES, INC.

                                      INDEX
                                                                            Page
                                                                            ----
PART I
FINANCIAL INFORMATION

     Item 1. Financial Statements

             Consolidated Balance Sheets as of June 30, 2000 (Unaudited)
               and December 31, 1999.......................................... 3

             Consolidated Statements of Operations and Comprehensive
               Loss (Unaudited) for the Three and Six Months Ended
               June 30, 2000 and 1999......................................... 4

             Consolidated Statements of Cash Flows (Unaudited) for
               the Six Months Ended June 30, 2000 and 1999.................... 5

             Notes to Consolidated Financial Statements (Unaudited)........... 6

     Item 2. Management's Discussion and Analysis

             Management's Discussion and Analysis of Financial Condition
               and Results of Operations...................................... 8

PART II
OTHER INFORMATION

     Item 6. Exhibits and Reports on Form 8-K.................................12

SIGNATURES....................................................................13

                                       2

<PAGE>


                                                               PART I
                                                        FINANCIAL INFORMATION


Item 1.  Financial Statements

<TABLE>
                                                   Human Pheromone Sciences, Inc.

                                                     Consolidated Balance Sheets

<CAPTION>
                                                                                                       June 30,         December 31,
(in thousands except share data)                                                                         2000              1999
--------------------------------------------------------------------------------                       --------          --------
                                                                                                     (unaudited)
<S>                                                                                                    <C>               <C>
Assets

Current assets:
  Cash and cash equivalents                                                                            $    761          $    108
  Accounts receivable, net of allowances of $38
   and $338 in 2000 and 1999, respectively                                                                1,185             2,050
  Inventories                                                                                               600             2,304
  Other current assets                                                                                       47                36
                                                                                                       --------          --------
Total current assets                                                                                      2,593             4,498

Property and equipment, net                                                                                   9                14
                                                                                                       --------          --------
                                                                                                       $  2,602          $  4,512
                                                                                                       ========          ========


Liabilities and Shareholders' Equity

Current liabilities:
  Bank borrowings                                                                                      $      0          $    900
  Accounts payable                                                                                           88               573
  Deferred revenue                                                                                          188                 0
  Accrued advertising                                                                                        83               313
  Accrued commissions                                                                                         0               286
  Other accrued expenses                                                                                    238               374
                                                                                                       --------          --------
Total current liabilities                                                                                   597             2,446
                                                                                                       --------          --------
Commitments and Contingencies

Shareholders' equity:
  Preferred stock, issuable in series, no par value, 10,000,000 shares
  authorized, 1,433,333 Series AA convertible shares issued and outstanding at
  June 30, 2000 and December 31, 1999, 17,010 and 14,203 Series BB convertible
  shares issued and outstanding at June 30, 2000 and December 31, 1999,
    respectively                                                                                          3,606             3,296
  Common stock, no par value, 13,333,333 shares authorized,
    3,429,839 shares issued and outstanding on each date                                                 17,667            17,667
  Accumulated deficit                                                                                   (19,208)          (18,847)
  Accumulated other comprehensive loss                                                                      (60)              (50)
                                                                                                       --------          --------
Total shareholders' equity                                                                                2,005             2,066
                                                                                                       --------          --------

                                                                                                       $  2,602          $  4,512
                                                                                                       ========          ========
<FN>

See accompanying notes to consolidated financial statements
</FN>
</TABLE>

                                                                 3

<PAGE>


<TABLE>
                                                   Human Pheromone Sciences, Inc.

                                    Consolidated Statements of Operations and Comprehensive Loss
                                                             (unaudited)


<CAPTION>
                                                                               Three months ended              Six months ended
                                                                                    June 30,                        June 30,
                                                                            -----------------------         -----------------------
(in thousands except per share data)                                          2000           1999             2000            1999
                                                                            -------         -------         -------         -------
<S>                                                                         <C>             <C>             <C>             <C>
Net product sales                                                           $   474         $ 1,724         $ 1,755         $ 3,886
License and supply revenues                                                     277             387             529             464
                                                                            -------         -------         -------         -------
Net revenues                                                                    751           2,111           2,284           4,350
Cost of goods sold                                                              140             757             686           1,536
                                                                            -------         -------         -------         -------

Gross profit                                                                    611           1,354           1,598           2,814

Operating Expenses:
   Research and development                                                      81              83             161             167
   Selling, general and administrative                                          590           1,538           1,778           3,201
                                                                            -------         -------         -------         -------

Total operating expenses                                                        671           1,621           1,939           3,368
                                                                            -------         -------         -------         -------

Loss from operations                                                            (60)           (267)           (341)           (554)

Other income and (expense)                                                                                                        0
   Interest (expense)                                                             0             (24)            (22)            (46)
   Other income (expense)                                                         4              (9)              2              (7)
                                                                            -------         -------         -------         -------
Total other income and (expense)                                                  4             (33)            (20)            (53)
                                                                            -------         -------         -------         -------

Net loss available to common shareholders                                       (56)           (300)           (361)           (607)

Other comprehensive loss - translation adjustment                                (3)            (11)            (10)            (48)
                                                                            -------         -------         -------         -------

Comprehensive loss                                                          $   (59)        $  (311)        $  (371)        $  (655)
                                                                            =======         =======         =======         =======


Net loss per common share-basic and diluted                                 $  (.02)        $  (.09)        $  (.11)        $  (.18)
                                                                            =======         =======         =======         =======


Weighted average common shares outstanding                                    3,430           3,430           3,430           3,430
                                                                            =======         =======         =======         =======
<FN>
See accompanying notes to consolidated financial statements
</FN>
</TABLE>

                                                                 4

<PAGE>


<TABLE>
                                                   Human Pheromone Sciences, Inc.

                                                Consolidated Statements of Cash Flows
                                                             (unaudited)

<CAPTION>
                                                                                                        Six months ended June 30,
                                                                                                      -----------------------------
(in thousands)                                                                                         2000                   1999
--------------------------------------------------------------------------------                      -------               -------
<S>                                                                                                   <C>                   <C>
Cash flows from operating activities
Net loss                                                                                              $  (361)              $  (607)
Adjustments to reconcile net loss
  to net cash provided by (used in) operating activities:
  Depreciation and amortization                                                                             7                    24
  Provision for sales returns and allowances                                                             (300)                 (610)

  Changes in operating assets and liabilities:
    Accounts receivable                                                                                 1,165                   961
    Inventories                                                                                         1,704                   234
    Other current assets                                                                                  (11)                  (10)
    Deferred revenue                                                                                      188                  --
Accounts payable and accrued liabilities                                                               (1,137)                 (367)
                                                                                                      -------               -------
Net cash provided by (used in) operating activities                                                     1,255                  (375)

Cash flows from investing activities
  Purchase of property and equipment                                                                       (2)                 --
                                                                                                      -------               -------
Net cash used in investing activities                                                                      (2)                 --

Cash flows from financing activities
  Proceeds from bank borrowings                                                                           150                   900
  Repayment of bank borrowings                                                                         (1,050)                 (773)
  Proceeds from issuance of convertible preferred stock                                                   310                   300
                                                                                                      -------               -------
Net cash (used in) provided by financing activities                                                      (590)                  427

Effect of exchange rate changes on cash                                                                   (10)                  (48)
                                                                                                      -------               -------

Net increase in cash and cash equivalents                                                                 653                     4
Cash and cash equivalents at beginning of period                                                          108                    77
                                                                                                      -------               -------
Cash and cash equivalents at end of period                                                            $   761               $    81
                                                                                                      =======               =======
Cash paid for interest                                                                                $   24                $    46
                                                                                                      =======               =======
<FN>
See accompanying notes to consolidated financial statements
</FN>
</TABLE>

                                                                 5

<PAGE>


                         Human Pheromone Sciences, Inc.

                   Notes to Consolidated Financial Statements
                                   (unaudited)

                                 March 31, 2000

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Nature of Operations

         Human Pheromone Sciences,  Inc. (the "Company") was incorporated in the
State of  California  in 1989 under the name of EROX  Corporation.  The  Company
changed the name to Human Pheromone  Sciences,  Inc. in May 1998. The Company is
engaged in the research, development,  manufacturing, marketing and licensing of
consumer  products  containing  synthetic human  pheromones as a component.  The
Company  initiated  commercial  operations  in  late  1994  with a line  of fine
fragrances and toiletries.

Basis of Presentation

         The accompanying  unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-QSB and Rule 10-01 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial statements. In the opinion of management,  all adjustments (consisting
of normal recurring accruals)  considered necessary for a fair presentation have
been  included.  Operating  results for the three and six months  ended June 30,
2000 are not necessarily  indicative of the results that may be expected for the
calendar year ending  December 31, 2000. For further  information,  refer to the
consolidated   financial  statements  and  footnotes  thereto  included  in  the
Company's annual report on Form 10-KSB for the year ended December 31, 1999.

Inventories

         Inventories  are  stated  at the  lower of cost  (first  in - first out
method) or market.  The  inventory at June 30, 2000  consists of finished  goods
inventory valued at $349,000,  work in process of $13,000,  and raw materials of
$238,000.  At December 31, 1999,  these  balances  were  $662,000,  $472,000 and
$1,170,000, respectively.

Capital Stock and Stock Options

         On June 30, 2000 the Company  sold 526 shares of Series BB  convertible
preferred stock for $50,000,  net of issuance  costs, to a current  shareholder.
The sale  enabled  the  Company's  net equity to remain in  compliance  with the
NASDAQ  Small Cap  listing  requirements.  No  assurances  can be given that the
Company will remain in compliance with these listing requirements in the future.

         On  March  26,  2000  the  Company  sold  2,271  shares  of  Series  BB
convertible  preferred  stock for $260,000,  net of issuance costs, to a current
shareholder. The cash was used to reduce bank borrowings.

         Outstanding  options to  purchase  shares of common  stock and  certain
common stock  equivalents were excluded from the computation of diluted earnings
per share since their effect would be antidilutive.

         During the three  months  ended June 30, 2000 no common  stock  options
were granted and no issued options were exercised.

                                       6

<PAGE>


License and Supply Revenue

         On April 24, 2000 the Company entered into a multi-year agreement under
which it licensed its Realm(R) fragrance and toiletry brands to Niche Marketing,
Inc. in exchange for a royalty on Niche Marketing  sales.  The license  includes
all territories excluding the Far East, which the company retains. The effective
date for this agreement was May 1, 2000.

         The sale of the Company's patented pheromones to licensees are reported
when the license fee revenues are earned.

                                       7

<PAGE>


Item 2. Management's Discussion and Analysis of Financial Conditions and Results
        of Operations

         This report contains  forward-looking  statements within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange  Act  of  1934,  as  amended.  Except  for  the  historical
information contained in this discussion and analysis of financial condition and
results  of  operations,  the  matters  discussed  herein  are  forward  looking
statements.  These forward looking statements include but are not limited to the
Company's  plans for sales  growth and  expansion  into new  channels  of trade,
expectations  of gross  margin,  expenses,  new  product  introduction,  and the
Company's   liquidity  and  capital  needs.  These  matters  involve  risks  and
uncertainties  that could cause  actual  results to differ  materially  from the
statements made. In addition to the risks and  uncertainties  described in "Risk
Factors",  below,  these risks and  uncertainties  may include  consumer trends,
business cycles,  scientific  developments,  changes in governmental  policy and
regulation,  currency  fluctuations,  economic  trends in the United  States and
inflation. These and other factors may cause actual results to differ materially
from those anticipated in forward-looking statements.  Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as
of the date hereof.

Risk Factors

         The  Company's  future  results  may be affected to a greater or lesser
degree by the following factors among others:

         The Company's marketing strategy may not be successful. The Company may
not be able to successfully  complete  negotiations  for licensing its pheromone
technology.  The Company may not be able to establish and maintain the necessary
sales and  distribution  channels.  The Company may not have sufficient funds to
successfully  market its  products  if the  current  marketing  strategy  is not
successful.

         The Company and/or its licensees may not be able to effectively compete
with larger  companies or with new products.  The prestige  fragrance  market is
extremely  competitive.  Many  fragrance  products  are  better  known  than the
Company's  products and compete for  advertising  and retail  shelf space.  Many
competitors have significantly greater resources that will allow them to develop
and  introduce  new  competing  products or increase  the  promotion  of current
products.

         The  product  life cycle of a  fragrance  can be very  short.  Changing
fashions  and fads can  dramatically  shift  consumer  preferences  and demands.
Traditional  fragrance  companies  introduce a new  fragrance  every year or so.
Changing  fashions and new products may reduce the chance of creating  long-term
brand loyalty to the Company's products.

         The  current  retail  environment  may cause  pricing  and  promotional
pressures.  Five  companies  control  the  majority  of the  sales  in the U. S.
department  store arena.  Because of their market share,  each company will have
significant power to determine the price and promotional terms which the Company
and/or its licensees  must meet in order to sell its products in the  department
stores.

         Seasonality  in sales  may cause  significant  variation  in  quarterly
results.  Sales in the  fragrance  industry are  generally  seasonal  with sales
higher in the second half of the year  because of  Christmas.  This  seasonality
could  cause  a  significant  variation  in the  Company's  quarterly  operating
results.

         The Company has reported  operating  losses in past years. No assurance
can be given that the Company will produce operating income in the future.

         The Company not be able to protect its technology or trade secrets. The
Company's  patents  and  patent  applications  may  not  protect  the  Company's
technology or ensure that the Company's  technology does not infringe  another's
valid  patent.  Others  may  independently   develop  substantially   equivalent
proprietary information.  The Company may not be able to protect its technology,
proprietary information or trade secrets.

         The Company may not be able to recruit  and retain key  personnel.  The
Company's  success  substantially  depends upon  recruiting  and  retaining  key
employees and  consultants  with  research,  product  development  and marketing
experience.  The Company may not be successful in recruiting and retaining these
key people.

                                       8

<PAGE>


         The Company relies upon other  companies to  manufacture  its products.
The  Company  relies  upon  Pherin  and  other   companies  to  manufacture  its
pheromones,  supply  components,  and to blend,  fill and package its  fragrance
products.   The  Company  may  not  be  able  to  obtain  or  retain  pheromones
manufacturers,  fragrance  suppliers,  or component  manufacturers on acceptable
terms.  If not, the Company may not be able to obtain  commercial  quantities of
its products. This would adversely affect operating results.

Results of Operations

Three  Months  ended June 30, 2000  compared to the Three  Months ended June 30,
1999

         On April 24, 2000 the Company entered into a multi-year agreement under
which it licensed its Realm(R) fragrance and toiletry brands to Niche Marketing,
Inc. in exchange for a royalty on Niche Marketing sales,  with guaranteed annual
minimum  payments  due to the  Company.  The license  includes  all  territories
excluding the Far East, which the company  retains.  The effective date for this
agreement was May 1, 2000.

         Net revenues for the second quarter of 2000 were $751,000  representing
a decrease of 64% from  revenues of  $2,111,000  for the prior  year's  quarter.
Approximately  86% of the  decrease is due to the  absence of  Realm(R)  product
sales for May and June, which was licensed to Niche  Marketing.  The license and
supply of pheromones under license  agreements  decreased by 28% to $277,000 for
the current year period.  The decreased license and supply revenue is due to the
reduced  requirements by Avon this year as reorder  quantities were not expected
to match last years initial manufacturing requirements for the product launch of
Perceive(R)  by Avon.  The  addition of the  Realm(R)  license to other  royalty
income help offset the reduced Avon demand.

         Net  revenues  for the  quarters  ended June 30,  2000 and 1999 were as
follows (in thousands).

--------------------------------------------------------------------------------
Markets                                                     2000           1999
--------------------------------------------------------------------------------
U.S. Retail & Distributor Markets                          $  379         $1,598
License and Supply Revenues                                   277            387
International Markets                                          95            126
                                                           ------         ------

Net Revenues                                               $  751         $2,111


         Gross  profit for the  quarter  ended  June 30,  2000  declined  55% to
$611,000 from $1,354,000 in the prior year due to the reduced sales volume. As a
percentage  of sales  gross  profit  of 81% was  better  than  last  year of 64%
reflecting the impact of the more profitable license and supply business.

         Research and  Development  expenses for the second quarters of 2000 and
1999 were $81,000 and $83,000,  respectively.  These costs  principally  reflect
payments and costs under the Company's consulting agreements in this area.

         Selling,  general and  administrative  expenses  decreased  $948,000 to
$590,000 in the first  quarter of 2000 from  $1,538,000  in the first quarter of
1999.  Advertising,  selling, and marketing expenses were $749,000 less than the
prior year as the licensee of the Realm(R) brand began  incurring these expenses
May 1,2000.  Distribution  expenses  were  reduced by  $42,000,  and general and
administrative  costs were $157,000  lower in the current  year's  quarter.  The
Company restructured the organization to reduce the overhead required to support
its efforts to focus on new product development,  and license  opportunities for
the patented pheromone technology.

         The  loss  from   operations  of  $60,000  was  $207,000  less,  a  78%
improvement  over  the 1999  second  quarter  operating  loss of  $267,000.  The
Company's  licensing of the Realm(R) Realm(R) brand,  which was effective May 1,
2000,  resulted in reduced net revenues but the significant savings in operating
expenses resulted in the reduced operating losses.

                                        9

<PAGE>


         The Company  incurred no net interest expense during the second quarter
of 2000,  and $24,000 in the second quarter of 1999. As a result of the licensee
agreement,  and subsequent sale of inventory,  the Company paid off the existing
bank line in April 2000.

Six Months ended June 30, 2000 as compared to the Six Months ended June 30, 1999

         Net revenues  for the six months  ended June 30, 2000 were  $2,284,000.
This was a 47% decrease  from net revenues of  $4,350,000  for the first half of
1999.  The lack of Realm(R)  brand  products sales in May and June caused by the
May 1  effective  date  of  the  license  agreement,  accounted  for  25% of the
decreased  revenues  for the first six months.  For the first four months of the
year the Realm(R)  revenues were down 22%for the comparable four months of 1999.
The license and supply revenues increased by $65,000 for the first six months of
2000 to $529,000. The Company realized six months of revenue in 2000 as compared
with 1999 which reflected the commencement of licensing revenue in March.

         Net  sales  for the six  months  ended  June  30,  2000 and 1999 are as
follows:

--------------------------------------------------------------------------------
Class of Trade                                             1999            1999
--------------------------------------------------------------------------------
U.S. Markets                                              $1,532          $3,635
License and Supply Revenues                                  529             464
International Markets                                        223             251
                                                          ------          ------
Net Sales                                                 $2,284          $4,350


         Gross profit for the first half of 2000 declined 43% to $1,598,000 from
$2,814,000 in 1999.  The decrease is the result of reduced  sales volume.  Gross
profit as a percentage of revenues improved to 70% compared to 65% in 1999, also
reflecting the impact of the more profitable license and supply business.

         Research and  Development  expenses for the first half of 2000 and 1999
were  $161,000  and  $167,000,  respectively  and are  principally  comprised of
payments under the Company's contract with Pherin Corporation.

         Selling, general and administrative expenses decreased to $1,778,000 in
the six months ended June 30, 2000 from  $3,201,000 in the period ended June 30,
1999. Selling marketing and advertising accounted for $1,157,000 of the decrease
with all  other  operational  areas  spending  less in 2000  than in  1999.  The
reduction  in  operating  expenses  of  $1,423,000  is  directly  related to the
Company's  decision to license the  Realm(R)  brand and  eliminate  the expenses
associated with directly to distributing with the department store accounts.

         The loss from operations  decreased by $213,000 to $341,000 for the six
months ended June 30, 2000,  from $554,000 in 1999.  The Company's  licensing of
the Realm(R)  brand has  resulted in reduced net  revenues  offset by savings in
operating  expenses that have  significantly  reduced the operating losses.  The
unprofitable  department  store sales channel has been  eliminated  and replaced
with a minimum royalty revenue source.

         The Company  incurred  $22,000 in net interest expense during the first
half of 2000  compared  to  $46,000  net  interest  expense  in 1999  due to the
repayment of the credit line borrowings in April 2000.

LIQUIDITY

         At June 30,  2000,  the  Company  had no  outstanding  borrowings,  and
working  capital  was  $1,996,000.  At  December  31,  1999 the  Company had net
borrowings of $900,000 and working capital of $2,052,000.  For the six months of
2000, net cash generated  from operating  activities was $1,255,000  compared to
$375,000  used  in  operating  activities  for  the  prior  year's  six  months.
Accordingly,  the Company had a net  repayment of its line of credit of $900,000
in the  first six  months of 2000,  while it had net  additional  borrowings  of
$127,000 in the first half year of 1999.

                                       10

<PAGE>


         On  July  1,  2000,   the  Company's   Business  Loan   Agreement  with
Mid-Peninsula  Bank  of Palo  Alto,  California  (the  "Bank")  providing  for a
continued line of credit expired. The Company may apply for a new credit line in
the future.

         Assuming the Company's activities proceed substantially as planned, the
Company's cash proceeds from the license to Niche  Marketing,  license  revenues
and  anticipated  revenues  from  product  sales  should be adequate to meet its
working capital needs over the next twelve months.  Working capital requirements
will primarily be for research, product development and administrative costs.

         Additional  working  capital may be required should the Company fail to
generate new products or new license revenues.  Furthermore,  additional working
capital may be required  should the Company  experience  a greater  than planned
success  with  its   products,   potential   products,   and  research   funding
requirements.  Funds would be needed for inventory  build,  accounts  receivable
financing and staffing  purposes.  If the Company fails to achieve revenues from
its 2000 marketing efforts,  or if product development proves to be more capital
intensive than planned, the Company may require additional funding.

         On June 30,  2000,  the  Company  obtained  $50,000  additional  equity
capital from a current  shareholder by issuing  shares of convertible  preferred
stock.

RECENT ACCOUNTING PRONOUNCEMENTS

         In June 1998, the FASB issued SFAS No. 133,  "Accounting for Derivative
Instruments  and  Hedging  Activities".  SFAS  No.  133  requires  companies  to
recognize  all  derivatives  contracts as either  assets or  liabilities  in the
balance sheet and to measure them at fair value. If certain  conditions are met,
a derivative may be specifically  designated as a hedge,  the objective of which
is to match the timing of gain or loss  recognition  on the  hedging  derivative
with the recognition of (i) the changes in the fair value of the hedged asset or
liability that are  attributable  to the hedged risk or (ii) the earnings effect
of the hedged  forecasted  transaction.  For a derivative  not  designated  as a
hedging  instrument,  the gain or loss is  recognized in income in the period of
change.  SFAS No. 133, as amended by SFAS No. 137, is  effective  for all fiscal
quarters of fiscal quarters of fiscal years beginning after June 15, 2000.

The Company has not entered into derivatives  contracts either to hedge existing
risks or for  speculative  purposes.  Accordingly,  the Company  does not expect
adoption  of the new  standard  on  January  1,  2001 to  affect  its  financial
statements.

In  December  1999,  the SEC issued  Staff  Accounting  Bulletin  (SAB) No. 101,
Revenue Recognition in Financial  Statements.  SAB No. 101 summarizes certain of
the staff's  views in  applying  generally  accepted  accounting  principles  to
revenue  recognition in financial  statements.  SAB No. 101 is effective for all
transactions  beginning with the second quarter of 2000. The Company has applied
SAB No. 101 where applicable.

                                       11

<PAGE>


                                     PART II
                                OTHER INFORMATION


Item 6.  Exhibits and Reports on Form 8-K

         (a)      Exhibit  10.21  Amendment  to  License  Agreement  with  Niche
                  Marketing, Inc.

         (b)      Exhibit 27.01-Financial Data Schedule

                                       12

<PAGE>


                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  had duly  caused  this  Report  to be  signed  on behalf by the
undersigned thereunto duly authorized.


                                            HUMAN PHEROMONE SCIENCES, INC.
                                            Registrant

Date:  August 14, 2000                      /s/ William P. Horgan
                                            ------------------------------------
                                            William P. Horgan
                                            Chairman and Chief Executive Officer




Date:  August 14, 2000                      /s/ Gregory S. Fredrick
                                            ------------------------------------
                                            Gregory S. Fredrick
                                            Vice President Finance

                                       13